Probiotics prevent Hirschsprung's disease-associated enterocolitis: A prospective multicenter randomized controlled trial

International Journal of Colorectal Disease

Volumn 30, Issue 1, 2014, Pages 105-110

  Wang, Xiaolin ^a   Li, Zhi ^a   Xu, Zhilin ^b   Wang, Zhongrong ^c   Feng, Jiexiong ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c ANHUI PROVINCIAL HOSPITAL   (China)

Author keywords

Hirschsprung's disease associated enterocolitis; Probiotics; Prospectivemulticenter randomized controlled trial

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

ADOLESCENT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; ENTEROCOLITIS; ENZYME IMMUNOASSAY; FEMALE; FLOW CYTOMETRY; HIRSCHSPRUNG DISEASE; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEWBORN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; BLOOD; CLINICAL TRIAL; COMPLICATION; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; SEVERITY OF ILLNESS INDEX;

ADMINISTRATION, ORAL; ADOLESCENT; ANTIGENS, CD4; ANTIGENS, CD8; CHILD; CHILD, PRESCHOOL; CYTOKINES; ENTEROCOLITIS; FEMALE; HIRSCHSPRUNG DISEASE; HUMANS; INFANT; MALE; PROBIOTICS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84926645099     PISSN: 01791958     EISSN: 14321262     Source Type: Journal    
DOI: 10.1007/s00384-014-2054-0     Document Type: Article

References (28)

1. Lilly DM, Stillwell RH (1965) Probiotics: growth promoting factors by microorganisms. Sci 147:747-748
2. Fuller R (1989) Probiotics in man and animals. J Appl Bacteriol 66: 365-378
3. Arnold C (2013) The pros and cons of probiotics. Lancet Infect Dis 13(7):571-572
4. Drouault-Holowacz S, Bieuvelet S, Burckel A, CazaubielM, Dray X, Marteau P (2008) A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Gastroenterol Clin Biol 32(2):147-152
5. Geier MS, Butler RN, Howarth GS (2007) Inflammatory bowel disease: current insights into pathogenesis and new therapeutic options; probiotics, prebiotics and synbiotics. Int J Food Microbiol 115(1):1-11
6. Imase K, Tanaka A, Tokunaga K, Sugano H, Ishida H, Takahashi S (2007) Lactobacillus reuteri tablets suppress Helicobacter pylori infection- a double-blind randomised placebo-controlled cross-over clinical study. Kansenshogaku Zasshi 81(4):387-393
7. Rafter J (2003) Probiotics and colon cancer. Best Pract Res Clin Gastroenterol 17(5):849-859
8. Barrons R, Tassone D (2008) Use of Lactobacillus probiotics for bacterial genitourinary infections in women: a review. Clin Ther 30(3):453-468
9. SchultzM, TimmerA, Herfarth HH, Sartor RB, Vanderhoof JA, Rath HC (2004) Lactobacillus GG in inducing and maintaining remission of Crohn’s disease. BMC Gastroenterol 4:5
10. Rosemary JY, Shari H (2003) Probiotic use in children. J Pediatr Health Care 17(6):277-283
11. Sari FN, Dizdar EA, Oguz S, Erdeve O, Uras N, Dilmen U (2011) Oral probiotics: Lactobacillus sporogenes for prevention of necrotizing enterocolitis in very low-birth weight infants: a randomized, controlled trial. Eur J Clin Nutr 65(4):434-439
12. Barclay AR, Stenson B, Simpson JH, Weaver LT, Wilson DC (2007) Probiotics for necrotizing enterocolitis: a systematic review. J Pediatr Gastroenterol Nutr 45(5):569-576
13. Kliegman RM (2005) Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants. J Pediatr 146(5):710
14. Lin HC, Su BH, Chen AC, Lin TW, Tsai CH, Yeh TF, OhW (2005) Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants. Pediatr 115(1):1-4
15. Austin KM (2012) The pathogenesis of Hirschsprung’s diseaseassociated enterocolitis. Semin Pediatr Surg 21(4):319-327
16. Blanarova C, GalovicovaA, PetrasovaD (2009) Use of probiotics for prevention of radiation-induced diarrhea. Bratisl Lek Listy 110(2): 98-104
17. Hackam DJ, Filler RM, Pearl RH (1998) Enterocolitis after the surgical treatment of Hirschsprung’s disease: risk factors and financial impact. J Pediatr Surg 33(6):830-833
18. Murphy F, Puri P (2005) New insights into the pathogenesis of Hirschsprung’s associated enterocolitis. Pediatr Surg Int 21(10): 773-779
19. Elhalaby EA, Coran AG, Blane CE, Hirschl RB, Teitelbaum DH (1995) Enterocolitis associated with Hirschsprung’s disease: a clinical-radiological characterization based on 168 patients. J Pediatr Surg 30(1):76-83
20. Caneiro P, Brereton R, Drake D et al (1992) Enterocolitis in Hirschsprung’s disease. Pediatr Surg Int 7:356-360
21. Teitelbaum DH, Cilley RE, Sherman NJ, Bliss D, Uitvlugt ND, Renaud EJ, Kirstioglu I, Bengston T, Coran AG (2000) A decade of experience with the primary pull-through for Hirschsprung disease in the newborn period: a multicenter analysis of outcomes. Ann Surg 232(3):372-380
22. De Filippo C, Pini-Prato A, Mattioli G, Avanzini S, Rapuzzi G, Cavalieri D, Di Paola M, Stefanini I, Ceccherini I, Mavilio D, Lionetti P, Jasonni V (2010) Genomics approach to the analysis of bacterial communities dynamics in Hirschsprung’s diseaseassociated enterocolitis: a pilot study. Pediatr Surg Int 26:465-471
23. Wilson-Storey D, Scobie W (1989) Impaired gastrointestinal mucosal defense in Hirschsprung’s disease: a clue to the pathogenesis of enterocolitis? J Pediatr Surg 24:462-464
24. Caniano DA, Teitelbaum DH, Qualman SJ, Shannon BT (1989) The piebald-lethal murine strain: investigation of the cause of early death. J Pediatr Surg 24:906-910
25. Aslam A, Spicer RD, Corfield AP (1997) Children with Hirschsprung’s disease have an abnormal colonic mucus defensive barrier independent of the bowel innervation status. J Pediatr Surg 32:1206-1210
26. Reis EA, Hagan JE, Ribeiro GS, Teixeira-Carvalho A, Martins- Filho OA, Montgomery RR, Shaw AC, Ko AI, Reis MG (2013) Cytokine response signatures in disease progression and development of severe clinical outcomes for leptospirosis. PLoS Negl Trop Dis 7(9):e2457
27. Imamura A, Puri P, O’Briain DS, Reen DJ (1992) Mucosal immune defence mechanisms in enterocolitis complicating Hirschsprung’s disease. Gut 33(6):801-806
28. Frykman PK, Short SS (2012) Hirschsprung-associated enterocolitis: prevention and therapy. Semin Pediatr Surg 21(4):328-335